Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer

1. Garon, E.B.
2. Reck, M.
3. Paz-Ares, L.
4. Ponce, S.
5. Jaime, J.C.
6. Juan, O.
7. Nadal, E.
8. Lee, P.
9. Dalal, R.
10. Liu, J.
11. He, S.
12. Treat, J.
13. Nakagawa, K.